Lupin

ESG Rating by NSE Sustainability Ratings & Analytics Limited.

09 Dec, 2025 | 06:01pm • Source: BSE

Lupin Receives Tentative Approval from U.S. FDA for Siponimod Tablets.

05 Dec, 2025 | 09:32am • Source: BSE

Lupin and Valorum Enter into an Exclusive Licensing Agreement for Biosimilar Armlupeg (Pegfilgrastim-unne) in the United States.

04 Dec, 2025 | 01:22pm • Source: BSE

Lupin Receives Approval from U.S. FDA for Biosimilar Armlupeg (Pegfilgrastim-unne).

01 Dec, 2025 | 07:44am • Source: BSE

Lupin Limited has informed the Exchange regarding a press release dated November 28, 2025, titled "Lupin Foundation Earns CRISIL s Highest VO 1A Rating for...

28 Nov, 2025 | 12:02pm • Source: NSE

Lupin Foundation Earns CRISIL''s Highest VO 1A Rating for Excellence in Social Responsibility.

28 Nov, 2025 | 11:42am • Source: BSE

U.S. FDA has conducted an inspection at Company''s manufacturing facility located at Goa, India.

21 Nov, 2025 | 10:47pm • Source: BSE

Lupin Limited has informed the Exchange regarding a press release dated November 14, 2025, titled "Lupin Launches Risperidone Long-Acting Injectable with 180-day CGT exclusivity in...

14 Nov, 2025 | 09:01am • Source: NSE

Lupin Launches Risperidone Long-Acting Injectable with 180-day CGT Exclusivity in the U.S., the first product from its proprietary Long-Acting Injectable platform PrecisionSphere.

14 Nov, 2025 | 07:22am • Source: BSE

Transcript of Q2 FY2026 Earnings Conference Call.

12 Nov, 2025 | 03:58pm • Source: BSE

Lupin Limited has informed the Exchange regarding a press release dated November 12, 2025, titled "Lupin Manufacturing Solutions Unveils Dedicated Oncology Block at Vizag, India

12 Nov, 2025 | 01:07pm • Source: NSE

Lupin Manufacturing Solutions Unveils Dedicated Oncology Block at Vizag, India.

12 Nov, 2025 | 12:57pm • Source: BSE

Intimation about participating in the Analyst/Investors Meet.

10 Nov, 2025 | 04:13pm • Source: BSE

Link of Audio Recording of the Earnings Call-Q2 FY26.

07 Nov, 2025 | 06:06pm • Source: BSE

The Company has informed the Exchange about the Investor Presentation on the Unaudited Financial Results for the Quarter and Half Year ended September 30, 2025.

06 Nov, 2025 | 07:14pm • Source: BSE

Lupin Q2 FY2026 Results

06 Nov, 2025 | 06:51pm • Source: BSE

Outcome of the Board Meeting for Approval of the Unaudited Standalone and Consolidated Financial Results of the Company for the Quarter and Half Year ended...

06 Nov, 2025 | 06:40pm • Source: BSE

Approval of the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and half year ended September 30, 2025.

06 Nov, 2025 | 06:30pm • Source: BSE

Lupin Receives EIR from U.S. FDA for its Pithampur Unit-3 Facility

05 Nov, 2025 | 05:52pm • Source: BSE

Newspaper Advertisement for the intimation regarding Special Window for re-lodgement for transfer request of physical shares.

31 Oct, 2025 | 06:10pm • Source: BSE